

ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

0

Patient Name	Mrs. VARTIKA SHARMA	Lab No	4028382
UHID	40012085	Sample Date	23/03/2024 3:16PM
Age/Gender	32 Yrs/Female	Report Date	23/03/2024 4:11PM
Prescribed By	Dr. EHS CONSULTANT	Bed No / Ward	OPD
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Company	Mediwheel - Arcofemi Health Care Ltd.		

CYTOLOGY

CYTOLOGY*

Type of Specimen

No. of smears examined

Adequacy

Endocervical cells

Inflammation

Organisms

Epithelial cell abnormality

Others

Impression

Note: Test marked as * are not accredited by NABL

Bethesda2014

Pap smear (Conventional)

Two

Satisfactory for evaluation.

Adequate

Not seen.

Moderate acute inflammation.


Not seen.

Not seen

-

Negative for intraepithelial lesion/ malignancy.

-----** End Of Report **-----



Dr. ABHINAV VERMA
MBBS|MD|INCHARGE PATHOLOGY

ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

Patient Name	Mrs. VARTIKA SHARMA	Lab No	4028382
UHID	40012085	Collection Date	23/03/2024 11:36AM
Age/Gender	32 Yrs/Female	Receiving Date	23/03/2024 11:52AM
IP/OP Location	O-OPD	Report Date	23/03/2024 5:20PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9782037636		

BIOCHEMISTRY

Test Name	Result	Unit	Biological Ref. Range	Sample: FI. Plasma
-----------	--------	------	-----------------------	--------------------

BLOOD GLUCOSE (FASTING)

BLOOD GLUCOSE (FASTING)	97.0	mg/dl	71 - 109
-------------------------	------	-------	----------

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

BLOOD GLUCOSE (PP)

BLOOD GLUCOSE (PP)	101.3	mg/dl	Non – Diabetic: - < 140 mg/dl Pre – Diabetic: - 140-199 mg/dl Diabetic: - >=200 mg/dl
---------------------	-------	-------	---

Sample: PLASMA

Method: Hexokinase assay.


Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

THYROID T3 T4 TSH

T3	1.010	ng/mL	0.970 - 1.690
T4	7.14	ug/dl	5.53 - 11.00
TSH	2.00	μIU/mL	0.40 - 4.05

Sample: Serum

RESULT ENTERED BY : Dr. ABHINAY VERMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

Patient Name	Mrs. VARTIKA SHARMA	Lab No	4028382
UHID	40012085	Collection Date	23/03/2024 11:36AM
Age/Gender	32 Yrs/Female	Receiving Date	23/03/2024 11:52AM
IP/OP Location	O-OPD	Report Date	23/03/2024 5:20PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9782037636		

BIOCHEMISTRY

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in the diagnosis of T3-hyperthyroidism the detection of early stages of hyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs a competitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA


Interpretation:-The determination of TSH serves as the initial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

LFT (LIVER FUNCTION TEST)

Sample: Serum

BILIRUBIN TOTAL	1.31 H	mg/dl	0.00 - 1.20
BILIRUBIN INDIRECT	0.98	mg/dl	0.20 - 1.00
BILIRUBIN DIRECT	0.33 H	mg/dl	0.00 - 0.30
SGOT	18.0	U/L	0.0 - 32.0
SGPT	17.5	U/L	0.0 - 33.0
TOTAL PROTEIN	7.6	g/dl	6.6 - 8.7
ALBUMIN	4.8	g/dl	3.5 - 5.2
GLOBULIN	2.8		1.8 - 3.6
ALKALINE PHOSPHATASE	64	U/L	35 - 104
A/G RATIO	1.7	Ratio	1.5 - 2.5
GGTP	13.0	U/L	0.0 - 40.0

RESULT ENTERED BY : Dr. ABHINAY VERMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

Patient Name	Mrs. VARTIKA SHARMA	Lab No	4028382
UHID	40012085	Collection Date	23/03/2024 11:36AM
Age/Gender	32 Yrs/Female	Receiving Date	23/03/2024 11:52AM
IP/OP Location	O-OPD	Report Date	23/03/2024 5:20PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9782037636		

BIOCHEMISTRY

BILIRUBIN TOTAL :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structure.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT (AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT (ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS :- Method: Biuret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.


ALBUMIN :- Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

ALKALINE PHOSPHATASE :- Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. **GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE** :- Method: Enzymatic colorimetric assay. Interpretation:- γ -glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

LIPID PROFILE

TOTAL CHOLESTEROL	196		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	42.0		High Risk :- <40 mg/dl (Male), <40 mg/dl (Female) Low Risk :- >=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	102.8		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	70 H	mg/dl	10 - 50
TRIGLYCERIDES	350		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	5	%	

RESULT ENTERED BY : Dr. ABHINAY VERMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

Patient Name	Mrs. VARTIKA SHARMA	Lab No	4028382
UHID	40012085	Collection Date	23/03/2024 11:36AM
Age/Gender	32 Yrs/Female	Receiving Date	23/03/2024 11:52AM
IP/OP Location	O-OPD	Report Date	23/03/2024 5:20PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9782037636		

BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.
interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders.

HDL CHOLESTEROL :- Method:-Homogenous enzymatic colorimetric method.
Interpretation:-HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease.

LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.
Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived from VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver.

CHOLESTEROL VLDL :- Method: VLDL Calculative


TRIGLYCERIDES :- Method: GPO-PAP enzymatic colorimetric assay.
Interpretation:-High triglyceride levels also occur in various diseases of liver, kidneys and pancreas.
DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

UREA	24.0	mg/dl	16.60 - 48.50
BUN	11.2	mg/dl	6 - 20
CREATININE	0.65	mg/dl	0.50 - 0.90
SODIUM	140.2	mmol/L	136 - 145
POTASSIUM	4.52	mmol/L	3.50 - 5.50
CHLORIDE	104.7	mmol/L	98 - 107
URIC ACID	3.81	mg/dl	2.4 - 5.7
CALCIUM	10.45 H	mg/dl	8.60 - 10.00

RESULT ENTERED BY : Dr. ABHINAY VERMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

Patient Name	Mrs. VARTIKA SHARMA	Lab No	4028382
UHID	40012085	Collection Date	23/03/2024 11:36AM
Age/Gender	32 Yrs/Female	Receiving Date	23/03/2024 11:52AM
IP/OP Location	O-OPD	Report Date	23/03/2024 5:20PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9782037636		

BIOCHEMISTRY

CREATININE - SERUM :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidney disease.

URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uric acid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake and kidney reabsorption.

POTASSIUM :- Method: ISE electrode. Interpretation:-Low level: Intake excessive loss from body due to diarrhea, vomiting renal failure, High level: Dehydration, shock severe burns, DKA, renal failure.

CHLORIDE - SERUM :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosis and alkalosis.
Increase: dehydration, kidney failure, some form of acidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogen concentration are seen in inadequate renal perfusion, shock, diminished blood volume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerular nephritis and UTI.


CALCIUM TOTAL :- Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may be observed in hypoparathyroidism, nephrosis, and pancreatitis.

Sample: WHOLE BLOOD EDTA

HBA1C	5.0	%		
			< 5.7%	Nondiabetic
			5.7-6.4%	Pre-diabetic
			> 6.4%	Indicate Diabetes
				Known Diabetic Patients
			< 7 %	Excellent Control
			7 - 8 %	Good Control
			> 8 %	Poor Control

Method : - Turbidimetric inhibition immunoassay (TINIA)
 Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient.
 The approximate relationship between HbA1C and mean blood glucose values during the preceding 2 to 3 months.

RESULT ENTERED BY : Dr. ABHINAY VERMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

Patient Name	Mrs. VARTIKA SHARMA	Lab No	4028382
UHID	40012085	Collection Date	23/03/2024 11:36AM
Age/Gender	32 Yrs/Female	Receiving Date	23/03/2024 11:52AM
IP/OP Location	O-OPD	Report Date	23/03/2024 5:20PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9782037636		

BLOOD BANK INVESTIGATION


Test Name	Result	Unit	Biological Ref. Range
-----------	--------	------	-----------------------

BLOOD GROUPING	"O" Rh Positive		
----------------	-----------------	--	--

Note :

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

RESULT ENTERED BY : Dr. ABHINAY VERMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY


ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

Patient Name	Mrs. VARTIKA SHARMA	Lab No	4028382
UHID	40012085	Collection Date	23/03/2024 11:36AM
Age/Gender	32 Yrs/Female	Receiving Date	23/03/2024 11:52AM
IP/OP Location	O-OPD	Report Date	23/03/2024 5:20PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9782037636		

CLINICAL PATHOLOGY

Test Name	Result	Unit	Biological Ref. Range	Sample: Urine
<u>URINE SUGAR (POST PRANDIAL)</u>				
URINE SUGAR (POST PRANDIAL)	NEGATIVE		NEGATIVE	Sample: Urine
<u>URINE SUGAR (RANDOM)</u>				
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	Sample: Urine
PHYSICAL EXAMINATION				
VOLUME	20	ml		Sample: Urine
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
PH	5.0 L		5.5 - 7.0	
SPECIFIC GRAVITY	1.010		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	0-1	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	1-2	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	

RESULT ENTERED BY : Dr. ABHINAY VERMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

Patient Name	Mrs. VARTIKA SHARMA	Lab No	4028382
UHID	40012085	Collection Date	23/03/2024 11:36AM
Age/Gender	32 Yrs/Female	Receiving Date	23/03/2024 11:52AM
IP/OP Location	O-OPD	Report Date	23/03/2024 5:20PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9782037636		


CLINICAL PATHOLOGY

BACTERIA NIL NIL
OHTERS NIL NIL

Methodology:-

Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific Gravity: Proton release from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue (Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method. interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

RESULT ENTERED BY : Dr. ABHINAY VERMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

Patient Name	Mrs. VARTIKA SHARMA	Lab No	4028382
UHID	40012085	Collection Date	23/03/2024 11:36AM
Age/Gender	32 Yrs/Female	Receiving Date	23/03/2024 11:52AM
IP/OP Location	O-OPD	Report Date	23/03/2024 5:20PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9782037636		


HEMATOLOGY

Test Name	Result	Unit	Biological Ref. Range
<u>CBC (COMPLETE BLOOD COUNT)</u>			
Sample: WHOLE BLOOD EDTA			
HAEMOGLOBIN	11.9 L	g/dl	12.0 - 15.0
PACKED CELL VOLUME(PCV)	37.5	%	36.0 - 46.0
MCV	101.4 H	fl	82 - 92
MCH	32.2 H	pg	27 - 32
MCHC	31.7 L	g/dl	32 - 36
RBC COUNT	3.70 L	millions/cu.mm	3.80 - 4.80
TLC (TOTAL WBC COUNT)	5.26	10 ³ / uL	4 - 10
<u>DIFFERENTIAL LEUCOCYTE COUNT</u>			
NEUTROPHILS	52.2	%	40 - 80
LYMPHOCYTE	39.7	%	20 - 40
EOSINOPHILS	2.7	%	1 - 6
BASOPHIL	0.6 L	%	1 - 2
MONOCYTES	4.8	%	2 - 10
PLATELET COUNT	2.05	lakh/cumm	1.500 - 4.500

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.
MCV :- Method:- Calculation bysystemex.
MCH :- Method:- Calculation bysystemex.
MCHC :- Method:- Calculation bysystemex.
RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia,High-Polycythemia.
TLC (TOTAL WBC COUNT) :- Method:-Optical Detectorblock based on Flowcytometry.Interpretation:-High-Leucocytosis, Low-Leucopenia.
NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry
LYMPHOCYTS :- Method: Optical detectorblock based on Flowcytometry
EOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry
MONOCYTES :- Method: Optical detectorblock based on Flowcytometry
BASOPHIL :- Method: Optical detectorblock based on Flowcytometry
PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.
HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia.
NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE) **38 H** mm/1st hr 0 - 15

RESULT ENTERED BY : Dr. ABHINAY VERMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

Patient Name	Mrs. VARTIKA SHARMA	Lab No	4028382
UHID	40012085	Collection Date	23/03/2024 11:36AM
Age/Gender	32 Yrs/Female	Receiving Date	23/03/2024 11:52AM
IP/OP Location	O-OPD	Report Date	23/03/2024 5:20PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9782037636		

Method:-Modified Westergrens.

Interpretation:-Increased in infections, sepsis, and malignancy.

RESULT ENTERED BY : Dr. ABHINAY VERMA

ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

Patient Name	Mrs. VARTIKA SHARMA	Lab No	4028382
UHID	40012085	Collection Date	23/03/2024 11:36AM
Age/Gender	32 Yrs/Female	Receiving Date	23/03/2024 11:52AM
IP/OP Location	O-OPD	Report Date	23/03/2024 5:20PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9782037636		

X Ray

Test Name	Result	Unit	Biological Ref. Range
-----------	--------	------	-----------------------

X-RAY CHEST P. A. VIEW

Both lung fields are clear.

Both CP angles are clear.

Both hemi-diaphragms are normal in shape and outlines.

Cardiac shadow is within normal limits.

Visualized bony thorax is unremarkable.

Correlate clinically& with other related investigations.

****End Of Report****

RESULT ENTERED BY : Dr. ABHINAY VERMA



Dr. SURESH KUMAR SAINI

MBBS,MD

RADIOLOGIST

DEPARTMENT OF CARDIOLOGY

UHID / IP NO	40012085 (8972)	RISNo./Status :	4028382/
Patient Name :	Mrs. VARTIKA SHARMA	Age/Gender :	32 Y/F
Referred By :	Dr. EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	23/03/2024 11:08AM/ OPSCR23-24/16527	Scan Date :	
Report Date :	23/03/2024 1:18PM	Company Name:	Final

REFERRAL REASON: HEALTH CHECKUP

2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

M MODE DIMENSIONS: -

		Normal		Normal
IVSD	9.6	6-12mm	LVIDS	24.0
LVIDD	35.7	32-57mm	LVPWS	15.8
LVPWD	9.1	6-12mm	AO	24.0
IVSS	15.8	mm	LA	30.1
LVEF	62-64	>55%	RA	-

DOPPLER MEASUREMENTS & CALCULATIONS:

STRUCTURE	MORPHOLOGY	VELOCITY (m/s)				GRADIENT (mmHg)	REGURGITATION
		E	0.82	e'	-		
MITRAL VALVE	NORMAL	A	0.62	E/e'	-	-	NIL
		E	0.53				
TRICUSPID VALVE	NORMAL	A	0.53			-	NIL
		E	1.28				
AORTIC VALVE	NORMAL		1.28			-	NIL
PULMONARY VALVE	NORMAL		0.65			-	NIL

COMMENTS & CONCLUSION: -

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 62-64%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS

DR SUPRIY JAIN
MBBS, M.D., D.M. (CARDIOLOGY)
INCHARGE & SR. CONSULTANT
INTERVENTIONAL CARDIOLOGY

DR ROOPAM SHARMA
MBBS, PGDCC, FIAE
CONSULTANT & INCHARGE
EMERGENCY, PREVENTIVE CARDIOLOGY
AND WELLNESS CENTRE

DEPARTMENT OF RADIO DIAGNOSIS

UHID / IP NO	40012085 (8972)	RISNo./Status :	4028382/
Patient Name :	Mrs. VARTIKA SHARMA	Age/Gender :	32 Y/F
Referred By :	Dr. EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	23/03/2024 11:08AM/ OPSCR23-24/16527	Scan Date :	
Report Date :	23/03/2024 1:04PM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

ULTRASOUND STUDY OF WHOLE ABDOMEN

- Liver:** Normal in size & echotexture. No obvious significant focal parenchymal mass lesion noted. Intrahepatic biliary radicals are not dilated. Portal vein is normal.
- Gall Bladder:** Lumen is clear. Wall thickness is normal. CBD is normal.
- Pancreas:** Normal in size & echotexture.
- Spleen:** Normal in size & echotexture. No focal lesion seen.
- Right Kidney:** Normal in shape, size & location. Echotexture is normal. Corticomedullary differentiation is maintained. No evidence of significant hydronephrosis or obstructive calculus noted.
- Left Kidney:** Normal in shape, size & location. Echotexture is normal. Corticomedullary differentiation is maintained. No evidence of significant hydronephrosis or obstructive calculus noted.
- Urinary Bladder:** Normal in size, shape & volume. No obvious calculus or mass lesion is seen. Wall thickness is normal.
- Uterus:** Normal in size, shape & anteverted in position. Endometrial thickness is normal. Endometrial cavity is empty. No mass lesion is seen. Cervix is normal.
- Both ovaries:** Bilateral ovaries are normal in size, shape & volume.
- Others:** No significant free fluid is seen in pelvic peritoneal cavity.

IMPRESSION: USG findings are suggestive of

- **No significant sonographic abnormality noted.**

Correlate clinically & with other related investigations.



DR. APOORVA JETWANI
Incharge & Senior Consultant Radiology
MBBS, DMRD, DNB
Reg. No. 26466, 16307